Valuation: AstraZeneca Pharma India Limited

Market Cap 152B 1.61B 1.44B 1.33B 1.2B 2.26B 2.29B 15.97B 6.29B 79.88B 6.04B 5.91B 253B P/E 2025
186x
P/E 2026 103x
Enterprise Value 149B 1.57B 1.4B 1.3B 1.18B 2.21B 2.24B 15.61B 6.15B 78.11B 5.91B 5.78B 247B EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
18.52%
Yield 2025
0.37%
Yield 2026 0.46%
1 day-1.81%
1 week+0.37%
Current month-3.24%
1 month-10.75%
3 months-23.95%
6 months-29.13%
Current year-33.54%
1 week 5,850
Extreme 5850
6,130.85
1 month 5,660
Extreme 5660
6,701
Current year 5,660
Extreme 5660
9,219.25
1 year 5,660
Extreme 5660
9,850
3 years 4,050.15
Extreme 4050.15
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 30/06/2025
Compliance Officer - 22/02/2026
Chief Tech/Sci/R&D Officer - 02/03/2025
Director TitleAgeSince
Director/Board Member 67 01/12/2016
Chairman 52 29/09/2024
Director/Board Member - 08/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.81%+0.37%-35.62%+30.46% 1.61B
+2.83%+4.40%+60.84%+123.50% 1,165B
+3.81%+5.66%+38.70%+74.91% 645B
+0.14%+0.63%+24.71%+95.03% 504B
-0.26%+2.95%+43.74%+64.34% 380B
-1.76%+1.41%+68.06%+43.41% 363B
-0.38%+2.89%+22.75%+51.83% 297B
-1.69%+2.46%+2.05%+26.26% 269B
+2.04%+3.05%+51.12%+60.42% 237B
+2.36%-0.11%+29.42%+102.04% 195B
Average -0.40%+2.59%+30.58%+67.22% 405.71B
Weighted average by Cap. -0.21%+3.17%+43.07%+83.07%

Financials

2025 2026
Net sales 17.16B 181M 162M 149M 136M 254M 258M 1.8B 708M 8.99B 680M 666M 28.49B 22.76B 240M 214M 198M 180M 337M 342M 2.38B 939M 11.92B 902M 882M 37.77B
Net income 1.16B 12.22M 10.91M 10.06M 9.14M 17.15M 17.41M 121M 47.75M 606M 45.86M 44.88M 1.92B 1.88B 19.8M 17.67M 16.3M 14.81M 27.78M 28.21M 196M 77.36M 982M 74.31M 72.72M 3.11B
Net Debt -5B -52.83M -47.15M -43.5M -39.52M -74.15M -75.29M -524M -206M -2.62B -198M -194M -8.31B -3.37B -35.58M -31.76M -29.3M -26.62M -49.94M -50.71M -353M -139M -1.77B -134M -131M -5.59B
Projected Income Statement - Annual - AstraZeneca Pharma India Limited
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
23/10/26 ₹5,988.15 -1.81% 288
22/10/26 ₹6,098.65 +0.36% 199
21/10/26 ₹6,076.90 +0.56% 1,073
19/10/26 ₹6,043.30 +1.29% 177
16/10/26 ₹5,966.05 +0.73% 117
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock